Publications

BibTex format

@article{Antepowicz:2021:10.1038/s41598-021-95150-z,
author = {Antepowicz, A and Habib, O and Kirsebom, F and Johansson, C and Gill, DR and Hyde, SC},
doi = {10.1038/s41598-021-95150-z},
journal = {Scientific Reports},
pages = {1--12},
title = {Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection},
url = {http://dx.doi.org/10.1038/s41598-021-95150-z},
volume = {11},
year = {2021}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Respiratory syncytial virus (RSV) infection is a common cause of hospitalisation in infants and the elderly. Palivizumab prophylaxis is the only approved treatment modality but is costly and only offered to select vulnerable populations. Here, we investigated gene delivery approaches via recombinant adeno-associated virus (rAAV2/8) and simian immunodeficiency virus (rSIV.F/HN) vectors to achieve sustained in vivo production of palivizumab in a murine model. Delivery of palivizumab-expressing vectors 28 days prior to RSV challenge resulted in complete protection from RSV-induced weight loss. This approach offers prophylaxis against RSV infection, allowing for wider use and reduction in treatment costs in vulnerable populations.
AU  - Antepowicz,A
AU  - Habib,O
AU  - Kirsebom,F
AU  - Johansson,C
AU  - Gill,DR
AU  - Hyde,SC
DO  - 10.1038/s41598-021-95150-z
EP  - 12
PY  - 2021///
SN  - 2045-2322
SP  - 1
TI  - Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection
T2  - Scientific Reports
UR  - http://dx.doi.org/10.1038/s41598-021-95150-z
UR  - https://www.nature.com/articles/s41598-021-95150-z
UR  - http://hdl.handle.net/10044/1/90954
VL  - 11
ER  -

Download

ProfessorCeciliaJohansson

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)